Drug Trial Radar · NCT06082050
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
7
Planned (sponsor's estimate)
Start
Nov 2, 2023
Primary completion
Jul 3, 2025
Study completion Feb 10, 2026
Sponsor
- Lead sponsor
- Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- YolTech Therapeutics Co., Ltd
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), as well as assessing the preliminary efficacy of subjects treated with YOLT-201.
Conditions
- Transthyroxin Amyloidosis Cardiomyopathy
Interventions
YOLT-201Drug
Infusion of YOLT-201 at Day 1, Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse event Adverse event Adverse eventsTime frame: hrough study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.